Industry priorities mirrored by Finnish Presidency
This article was originally published in Clinica
Executive Summary
The development of innovation policy and better regulation - key issues for the EU medtech industry - remain at the top of the EU agenda for the next six months. Mauri Pekkarinen, the Finnish trade minister, has confirmed that these issues, along with internal market matters, will be priorities of the current Finnish EU Council presidency.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.